What makes K2VITAL different from regular MK-7 supplements?

K2VITAL uses a patented microencapsulation technology (Delta form) that coats MK-7 molecules to prevent chemical degradation when combined with divalent minerals like calcium and magnesium in the same tablet or capsule. Standard MK-7 can lose up to 90% of its potency within weeks when co-formulated with calcium, whereas Kappa Bioscience has published stability studies showing K2VITAL retains greater than 95% potency under the same conditions. This makes K2VITAL particularly relevant for all-in-one bone health formulas combining both nutrients.

What is the recommended dosage of K2VITAL MK-7?

Clinical studies supporting bone and cardiovascular benefits have primarily used 180 mcg/day of MK-7, which is the dose used in the key 3-year postmenopausal RCT by Knapen et al. The European Food Safety Authority (EFSA) has established an adequate intake of 70 mcg/day for adults, while many bone health protocols use 90–200 mcg/day. Doses up to 360 mcg/day have been used in research without reported safety concerns in healthy adults not taking anticoagulants.

How long does it take for K2VITAL MK-7 to show results for bone health?

Improvements in biochemical markers such as the ratio of carboxylated to uncarboxylated osteocalcin (cOC:ucOC) can be detected within 4–8 weeks of consistent MK-7 supplementation at 180 mcg/day. Measurable changes in bone mineral density, as observed by dual-energy X-ray absorptiometry (DEXA), typically require at least 12–24 months of continuous supplementation, based on the Knapen 3-year trial. Vascular stiffness improvements were detected after 3 years in the same study cohort, suggesting cardiovascular benefits require longer intervention periods.

Can you take K2VITAL with vitamin D3?

Yes, and co-administration is frequently recommended because vitamin D3 (cholecalciferol) upregulates the synthesis of osteocalcin and matrix Gla protein, while MK-7 provides the carboxylation activity needed to activate these proteins. Without adequate vitamin K2, vitamin D3-stimulated increases in osteocalcin production may remain biologically inactive (undercarboxylated), potentially contributing to soft-tissue calcium deposition. Several commercial formulations combine K2VITAL with D3 at a typical ratio of 45–100 mcg MK-7 per 1000–5000 IU D3.

Does K2VITAL MK-7 interact with blood thinners like warfarin?

Yes, this is the most important drug interaction for MK-7. Warfarin works by inhibiting vitamin K epoxide reductase (VKORC1), thereby reducing the production of active clotting factors II, VII, IX, and X. Supplemental MK-7, with its uniquely long plasma half-life of approximately 72 hours, provides a sustained competitive substrate that can consistently counteract warfarin's mechanism and raise INR unpredictably. Patients anticoagulated with warfarin or other vitamin K antagonists should avoid MK-7 supplementation unless directly supervised by a physician with frequent INR testing.

Is K2VITAL MK-7 safe for children and adolescents?

K2VITAL MK-7 is generally recognized as safe for children and adolescents, as vitamin K2 naturally occurs in foods and is essential for proper bone development during growth years. However, dosing for pediatric populations should be determined by a healthcare provider, as established pediatric dosage guidelines for supplemental MK-7 are limited. Children taking anticoagulant medications should consult their doctor before using K2VITAL due to potential interactions with blood-thinning therapy.

How does K2VITAL MK-7 bioavailability compare to other vitamin K2 forms like MK-4?

K2VITAL is a natto-derived MK-7 with a longer half-life in the body (approximately 72 hours) compared to MK-4, allowing for less frequent dosing and more sustained blood levels. This extended retention time theoretically allows K2VITAL to accumulate in bone and vascular tissues more effectively than shorter-chain K2 variants. The branched-chain structure of MK-7 also enables better absorption when taken with dietary fats compared to some alternative K2 forms.

Does K2VITAL MK-7 require fat intake for optimal absorption?

Yes, K2VITAL MK-7 is a fat-soluble vitamin and is best absorbed when consumed with a meal containing dietary fat, such as oils, nuts, or fatty fish. Taking K2VITAL with vitamin D3 and a fat-containing meal may enhance the synergistic effect of both fat-soluble vitamins on calcium regulation and bone health. Absorption can be significantly reduced if K2VITAL is taken on an empty stomach or without adequate dietary fat.

K2VITAL (Vitamin K2 MK-7)

K2VITAL is a patented, microencapsulated form of menaquinone-7 (MK-7), the long-chain vitamin K2 isoform produced by Bacillus subtilis natto fermentation. It activates vitamin K-dependent proteins osteocalcin and matrix Gla protein (MGP) to direct calcium into bone and away from arterial walls.

Category: Other Evidence: 2/10 Tier: Emerging

K2VITAL (Vitamin K2 MK-7) — Hermetica Encyclopedia

Origin & History

K2VITAL is a branded form of Vitamin K2 as menaquinone-7 (MK-7), produced through a patented chemical synthesis process yielding 99.7% all-trans MK-7, the bioactive form identical to naturally occurring MK-7. Unlike fermentation-derived MK-7 from bacteria like Bacillus subtilis (found in natto), K2VITAL uses organic synthesis starting from menadiol with a heptaprenyl chain attachment, involving alkylation, halogenation, oxidation, and chromatographic purification.

Historical & Cultural Context

K2VITAL has no documented traditional or historical use as it is a modern synthetic branded ingredient. While MK-7 is historically associated with natto (fermented soybeans) in Japanese culture for bone and heart health, K2VITAL is produced through chemical synthesis rather than traditional fermentation methods.

Health Benefits

• Supports bone health by enabling osteocalcin carboxylation for calcium binding (mechanism established, but no K2VITAL-specific clinical trials cited)
• May help prevent arterial calcification through matrix Gla protein activation (general MK-7 mechanism, no K2VITAL-specific evidence provided)
• Directs calcium to bones rather than soft tissues via gamma-carboxylase enzyme activation (theoretical benefit based on MK-7 mechanism)
• Potential cardiovascular support through gene expression pathways (mechanism described, but no clinical evidence for K2VITAL)
• Enhanced bioactivity due to 99.7% all-trans isomer purity compared to mixed isomer forms (bioequivalence confirmed, therapeutic outcomes not studied)

How It Works

MK-7 serves as a cofactor for gamma-glutamyl carboxylase (GGCX), the enzyme that carboxylates glutamic acid residues on osteocalcin, enabling it to bind hydroxyapatite and incorporate calcium into bone matrix. Simultaneously, MK-7 carboxylates matrix Gla protein (MGP), which inhibits vascular smooth muscle calcification by sequestering free calcium ions in arterial tissue. K2VITAL's microencapsulation technology protects MK-7 from degradation by minerals like calcium and magnesium in combined supplement formulas, preserving bioavailability and ensuring consistent plasma MK-7 elevation for the compound's estimated 72-hour half-life.

Scientific Research

The research dossier reveals a significant gap in clinical evidence for K2VITAL specifically, with no human clinical trials, RCTs, or meta-analyses cited, and no PubMed PMIDs provided. Only one bioequivalence study compared K2VITAL to fermentation-derived MK-7 using a single 180 μg dose, confirming equivalent pharmacokinetics but reporting no therapeutic outcomes or sample size.

Clinical Summary

Human pharmacokinetic studies on MK-7 (the active compound in K2VITAL) demonstrate that doses of 90–360 mcg/day significantly raise plasma MK-7 concentrations and increase the percentage of carboxylated osteocalcin (cOC) relative to uncarboxylated osteocalcin (ucOC), a validated biomarker of vitamin K status. A 3-year randomized controlled trial in 244 healthy postmenopausal women (MenacalTM study, 2013) found 180 mcg/day MK-7 significantly improved bone mineral density at the lumbar spine and femoral neck versus placebo. Knapen et al. (2015) reported that 180 mcg/day MK-7 for 3 years reduced arterial stiffness markers, including carotid-femoral pulse wave velocity, in healthy postmenopausal women. No large-scale trials have been conducted using the K2VITAL brand specifically; existing efficacy data derives from studies using MK-7 of comparable purity, and K2VITAL's manufacturer (Kappa Bioscience) has published stability data but not independent brand-specific clinical outcomes.

Nutritional Profile

K2VITAL is a patented, pure synthetic menaquinone-7 (MK-7) vitamin K2 ingredient manufactured by Kappa Bioscience (Norway) via chemical synthesis rather than fermentation, yielding a highly pure, allergen-free, soy-free, and non-GMO form of MK-7. Active compound: all-trans menaquinone-7 (MK-7) — the biologically active trans isomer, typically standardized at concentrations of 100–3200 mcg MK-7 per gram of ingredient depending on formulation grade (e.g., K2VITAL DELTA, K2VITAL 0.2%). Macronutrients: negligible — MK-7 is a fat-soluble micronutrient with no meaningful protein, carbohydrate, or fiber content at functional dosing levels (typical human doses: 45–360 mcg/day). Fat-soluble vitamin: MK-7 belongs to the vitamin K family (naphthoquinone structure with a 7-isoprene side chain); requires dietary fat for intestinal absorption via chylomicron incorporation. Bioavailability: MK-7 has superior bioavailability and half-life (~3 days) compared to vitamin K1 (phylloquinone, half-life ~1–2 hours) and MK-4 (half-life ~1–2 hours), enabling once-daily dosing. K2VITAL's synthetic all-trans purity (>97% all-trans isomers) is a key differentiator, as fermentation-derived MK-7 (e.g., from Bacillus subtilis natto) can contain cis-isomers (up to 10–15%) that are biologically inactive and may reduce overall efficacy. Cofactor role: MK-7 acts as a cofactor for gamma-glutamyl carboxylase enzyme, enabling carboxylation of vitamin K-dependent proteins (VKDPs) including osteocalcin (bone) and matrix Gla protein (MGP, vascular tissue). No meaningful caloric contribution at supplemental doses. Stability: K2VITAL DELTA encapsulated form provides enhanced stability against oxidation and interaction with minerals (e.g., calcium, magnesium) in multivitamin matrices — a known degradation issue with unprotected MK-7.

Preparation & Dosage

K2VITAL is standardized to 99.7% all-trans MK-7 with a bioequivalence trial using 180 μg single dose. General MK-7 studies (not K2VITAL-specific) typically use 100-360 μg/day, but no clinically studied dosage ranges for K2VITAL forms are documented. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin D3, Calcium, Magnesium, Vitamin A, Boron

Safety & Interactions

MK-7 at supplemental doses (45–360 mcg/day) is generally well-tolerated with no significant adverse effects reported in clinical trials up to 3 years in duration. The most clinically significant interaction is with warfarin (coumadin) and other vitamin K antagonist anticoagulants; MK-7's long half-life (~72 hours) can produce sustained elevation of clotting factor activity, potentially destabilizing INR control and reducing anticoagulant efficacy. Individuals on anticoagulant therapy should not supplement MK-7 without physician supervision and frequent INR monitoring. Pregnancy safety data for supplemental MK-7 doses above dietary levels is limited; while dietary vitamin K2 is considered safe, high-dose supplementation during pregnancy or lactation should be approached cautiously and discussed with a healthcare provider.